GCAR1
Phase 1Cell therapy
GCAR1 is one of 19 biologic programs targeting Alveolar Soft Part Sarcoma. It is currently in Phase 1.
1
Indications
5
Total Trials
4
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Alveolar Soft Part Sarcoma
#DrugCompanyPhaseTrials
1DTIC-Dome
BayerPhase 3
Crestor
AstraZenecaPhase 3
Lanoxin
AAdvanz Pharma
Phase 3
Tecentriq
RochePhase 2
Sutent
PfizerPhase 2
Keytruda
Merck & Co.Phase 2
Votrient
NovartisPhase 2
Coumadin
AAbbott
Phase 2
Tylenol
KKenvue Brands
Phase 2
Synthroid
IInstitut Jerome Lejeune
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alveolar Soft Part Sarcoma4 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GCAR1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- AAHS Cancer Control Alberta